NCT06123286
Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms
Recruiting
EARLY_PHASE1Ages 18+InterventionalSupportive carePhilip ChangInvestigator-initiated
~30 participants
Updated 2026-08-04 on ClinicalTrials.gov
What's tested:Tart CherryOmega 3 FA (Fish Oil)
At a glance
Recruiting sites
1 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The primary objective is to assess changes in joint function between groups.
Measured over 6 Months
Conditions
Where it's being run
2 sites across 1 statesCalifornia2
Study leadership
- Philip Chang, DO · PRINCIPAL_INVESTIGATOR · Cedars-Sinai Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Breast cancer diagnosis (Stage I-III) with any hormonal status.
Females aged ≥ 18 years.
Currently receiving AI therapy.
BMI ≥ 27.
Clinical diagnosis of AIMSS.
Omega-3 Index \<8%.
Average joint pain score ≥ 4 on the Brief Pain Inventory (BPI) within 7 days of enrollment.
Written informed consent obtained from subject and ability and willingness of subject to comply with the requirements of the study.
Exclusion
Current use of anticoagulant medications (Including but not limited to Warfarin, Lovenox, Eliquis, Xarelto).
Allergy to cherries or fish/fish products.
Lifetime history of rheumatoid arthritis and/or inflammatory joint diseases (Including but not limited to reactive arthritis, ankylosing spondylitis, and psoriatic arthritis).
Uncontrolled diabetes mellitus as determined by treating physician (with or without the use of glucose lowering medications and/or insulin).
Lifetime history of stroke or transient ischemic attacks.
New use or dose change of oral or topical analgesics in the previous 14 days. (Including but not limited to opioids, non-steroidal anti-inflammatories, acetaminophen, SNRI's, SSRI's, gabapentinoids, tricyclic antidepressants, and muscle relaxants).
Oral or intra-articular steroid use in the previous 30 days (Including but not limited to dexamethasone, prednisone, methylprednisolone, triamcinolone, hydrocortisone).
History of joint fracture or surgery of the symptomatic joint in the previous 6 months.
What this trial measures
- The primary objective is to assess changes in joint function between groups.6 Months
Changes in joint symptoms will be assessed via the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). The WOMAC Pain score ranges from 0% to 100% with higher scores indicating greater difficulty with activities of daily living.